Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 16c, Misses on Revenue; Offers FY24 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024 4:16 PM EDTAchieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products
FIRDAPSE® Q1 2024 Net Product Revenues of $66.8 Million, a 16.2% YoY Increase
Robust Revenue Momentum for FIRDAPSE®
Successfully Commenced the U.S. Launch of AGAMREE® on March 13, 2024
Reported AGAMREE® Q1 2024 Net Product Revenues of $1.2 Million for the First Two Weeks of Commercial Availability
Early AGAMREE® Launch Indicators Highlight Promising Product Uptake Surpassing Initial Expectations
Q1 2024... More
